OBJECTIVE To determine the prevalence of left ventricular hypertrophy (LVH) and its associated risk factors in lupus nephritis (LN) patients. METHODS 287 LN patients (age: 38.54 ± 13.31, 262 female) were recruited. Echocardiography and serum high-sensitivity C-reactive protein (hs-CRP) were measured. Their relationship was evaluated by univariate correlation analysis and multivariate regressi...

BACKGROUND Silent ischaemia has been reported to be associated with an increased risk of myocardial infarction and sudden death in a wide range of patient groups. The aim of this study was to examine the prevalence of silent ischaemia in hypertensive patients with and without left ventricular hypertrophy (LVH). METHODS Twenty hypertensive patients participating in the Anglo-Scandinavian Cardi...

Introduction The presence of left ventricular hypertrophy (LVH) in patients with Chronic Kidney Disease (CKD) is associated with worsening cardiovascular outcomes. There is a dearth of data on LVH in Ghanaian CKD patients. Methods This was a cross sectional study carried out at the Komfo Anokye Teaching Hospital (KATH) in Kumasi, Ghana. A questionnaire was used to obtain information on clinic...

The heart carries out its pumping function by converting the chemical energy stored in fatty acids and glucose into the mechanical energy of actin-myosin interaction of myofibrils. Development of congestive heart failure is usually preceded by a period of compensated left ventricular hypertrophy (LVH) and alterations in myocardial bioenergetics have been considered to play an important role in ...

Background Fabry disease is a rare X-linked condition that results in storage of sphingolipids in multiple organs including the heart. The cardiac phenotype consists mainly of conduction abnormalities, left ventricular hypertrophy (LVH) and disease progression (fibrosis, arrhythmias and heart failure). CMR LGE classically shows basal inferolateral LGE. Native T1 mapping has recently shown a low...

Background Sarcomeric gene mutations are responsible for hypertrophic cardiomyopathy (HCM). In gene mutation carriers without significant left ventricular (LV) hypertrophy (G +LVH-), subtle abnormalities can exist as mitral valve elongation, crypts, markers of elevated LV systolic function, and abnormal apical trabeculation. Reverse curvature of the interventricular septum into the LV is a char...

The development left ventricular hypertrophy (LVH) represents a critical milestone in patients with hypertensive heart disease (HHD). This structural remodeling and the associated abnormalities in diastolic function portend an increased risk of both mortal and morbid events (1–4). Treatment that results in the regression of LVH is associated with a reduction in these event rates (5–8). However,...

BACKGROUND The present study examined the role of aldosterone in left ventricular hypertrophy (LVH) and geometry in patients with untreated essential hypertension (EHT), and investigated the contribution of myocardial fibrosis to the process of LVH. METHODS AND RESULTS The relationship of the plasma aldosterone concentration (PAC) to LVH and left ventricular (LV) geometry was investigated in ...

The aim of this study was to determine the prevalence of left ventricular hypertrophy (LVH), left ventricular diastolic dysfunction (LVDD) and left ventricular systolic dysfunction (LVSD) in a group of elderly Spanish individuals. Data were obtained on a subgroup of 371 individuals from the Lista district of Madrid, Spain who were taking part in the EPICARDIAN study. In hypertensive subjects, t...

Background Patients with left ventricular hypertrophy (LVH), typically assessed by 2D echocardiography, are at a greater risk for heart failure and sudden cardiac death. An accurate diagnosis of LVH is essential to clinical evaluation and treatment. However, 2D echo has inferior spatial resolution and less than optimal measurement positioning, relative to cardiac MRI. This “real-world” study, b...